Primary CNS Lymphoma
Anti-CD94 Monoclonal Antibody Dibotatug-Induced Response in a Refractory Primary CNS T-Cell Lymphoma.
Grommes C, et al
A patient with refractory primary CNS T-cell lymphoma achieved a clinical response following treatment with dibotatug, an anti-CD94 monoclonal antibody, marking a notable outcome in a disease with very limited therapeutic options. Primary CNS T-cell lymphoma is an exceptionally rare and aggressive m…
Source →Elevated Expression of Caveolin-1 Reflects a Poor Prognosis in Patients With Primary Central Nervous System Lymphomas.
Sugita Y, et al
A study of 39 patients with primary central nervous system lymphomas (PCNSLs, all CNS diffuse large B-cell lymphomas) found that high Caveolin-1 (Cav-1) expression — defined as an H-score ≥ 20 — is significantly associated with markedly lower patient survival compared to those with no or low H-score…
Source →Primary central nervous system extranodal NK/T-cell lymphoma predominantly composed of anaplastic cells: A case report.
Chen H, et al
Researchers describe what is believed to be the first reported case of a primary central nervous system extranodal NK/T-cell lymphoma (ENKTL) exhibiting a predominantly anaplastic morphology, occurring in a 79-year-old woman who presented with episodic seizures, left-sided limb weakness, altered men…
Source →Comparison of Thiotepa, Busulfan, and Cyclophosphamide Versus Busulfan and Thiotepa Conditioning Regimens in Autologous Stem Cell Transplantation for Primary CNS Lymphoma: A Multicenter Retrospective Analysis.
Jeong E, et al
In a multicenter retrospective study of 67 patients aged 60 or younger with primary central nervous system lymphoma (PCNSL), the thiotepa-busulfan-cyclophosphamide (TBC) conditioning regimen demonstrated significantly superior 3-year progression-free survival (PFS) compared to busulfan-thiotepa (BuT…
Source →Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
Blay J, et al
A landmark retrospective study with a median follow-up of 35 years reports that three of 43 patients with primary central nervous system lymphoma (PCNSL) treated with the C5R regimen remain alive and disease-free at 27, 28, and 44 years after treatment, demonstrating that very long-term survival is …
Source →Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study.
Scheichel F, et al
In patients with Primary Large-B-Cell Lymphoma of the CNS (PCNS-LBCL), radiological tumor regression during corticosteroid therapy was strongly associated with longer survival, with a median overall survival of 31.4 months in responders compared to only 3.9 months in patients whose tumors progressed…
Source →Spatial pattern-driven interpretable model and biological correlates in brain glioblastoma-lymphoma differentiation.
Wang Y, et al
A multicenter artificial-intelligence study of 1,109 patients across five centers showed that a spatial radiomics classifier can distinguish primary CNS lymphoma (PCNSL) from glioblastoma (GBM) on standard MRI with an external-test area under the ROC curve of 0.98, outperforming conventional radiomi…
Source →Advances in CAR-T therapy for central nervous system lymphoma.
Feng X, et al
A narrative review published in Frontiers in Immunology finds that while CAR-T cell therapy has transformed the management of relapsed and refractory B-cell lymphomas broadly, its application to central nervous system lymphoma — both primary (PCNSL) and secondary (SCNSL) — remains hampered by safety…
Source →Timing of autologous stem cell transplantation and induction response in central nervous system lymphoma.
Higuchi Y, et al
A retrospective single-center study of 12 patients with central nervous system lymphoma found that high-dose busulfan and thiotepa conditioning followed by autologous stem cell transplantation (BuTT/ASCT) is highly effective when performed promptly after achieving complete remission, with all 9 upfr…
Source →No association between temozolomide maintenance and survival after first-line treatment in primary CNS lymphoma.
Chowdhury N, et al
A study published in HemaSphere found no significant association between temozolomide maintenance therapy and improved survival outcomes in patients with primary central nervous system lymphoma (PCNSL) following first-line treatment. The research examined whether continuing temozolomide as a post-in…
Source →Severe Central Nervous System Fungal Infection Following Tirabrutinib Administration in a Patient with Refractory Primary Central Nervous System Lymphoma: A Case Report.
Akimoto J, et al
A case report published in NMC Case Reports Journal describes a fatal Aspergillus cerebral vasculitis that developed in a man in his 50s with refractory primary CNS lymphoma (CD20-positive diffuse large B-cell lymphoma) following administration of tirabrutinib, an oral Bruton's tyrosine kinase (BTK)…
Source →Vitreoretinal Lymphoma: A Comprehensive Clinical Review and Current Standards in Management.
Maitray A, et al
A comprehensive clinical review of vitreoretinal lymphoma concludes that no standardized treatment protocol currently exists for this rare ocular malignancy, which frequently progresses to central nervous system involvement and carries a poor overall prognosis despite often good initial responses to…
Source →Primary CNS lymphoma: Survival after craniotomy with resection versus stereotactic biopsy and the clinical impact of the "vanishing tumor" phenomenon.
Glinka P, et al
In a retrospective cohort study of 56 adults with primary central nervous system lymphoma (PCNSL) treated in Warsaw between 2015 and 2023, patients who underwent craniotomy with resection showed significantly longer median overall survival than those who received stereotactic biopsy (465 vs. 149.5 d…
Source →Autologous Stem Cell Transplant for HIV-Associated Lymphoma: A Systematic Review and Meta-Analysis.
Comelles MF, et al
A systematic review and meta-analysis of six prospective studies found that autologous stem cell transplantation (ASCT) yields encouraging survival outcomes in HIV-associated lymphoma, with estimated two-year overall survival of 79.8% (95% CI: 68.1–89.3) and two-year progression-free survival of 77.…
Source →Redefining consolidation in primary CNS lymphoma: autologous stem-cell transplantation as the standard.
Schaff LR, et al
A publication in The Lancet argues for autologous stem-cell transplantation (ASCT) as the new standard of care for consolidation therapy in primary CNS lymphoma (PCNSL), a rare and aggressive brain cancer. The article reframes the consolidation debate in PCNSL — a disease phase critical to preventin…
Source →